MedTrace Logo

Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD

NCT00501293 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 163

Last updated 2017-04-26

Study results available
· View outcomes & findings →

Summary

To evaluate the long-term, safety of Methylphenidate Transdermal System (MTS) in aged 13-17 years diagnosed withADHD

Conditions

  • ADHD

Interventions

DRUG

Methylphenidate Transdermal System

One of 4 doses of the MTS transdermal patch over the same duration of wear for approximately 6 months

Sponsors & Collaborators

  • Noven Therapeutics

    lead INDUSTRY

Principal Investigators

  • Robert L. Findling, M.D. · University Hospitals Cleveland Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
13 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2009-02-28
Completion
2009-02-28

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00501293 on ClinicalTrials.gov